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Purpose: Lynch syndrome (LS) screening can significantly reduce
cancer morbidity and mortality in mutation carriers. Our aim was
to identify cost-effective LS screening programs that can be
implemented in the “real world.”
Methods: We performed a systematic review of full economic
evaluations of genetic screening for LS in different target
populations; health outcomes were estimated in life-years gained
or quality-adjusted life-years.
Results: Overall, 20 studies were included in the systematic review.
Based on the study populations, we identified six categories of LS
screening program: colorectal cancer (CRC)–based, endometrial
cancer–based, general population–based, LS family registry–based,
cascade testing–based, and genetics clinic–based screening pro-
grams. We performed an in-depth analysis of CRC-based LS
programs, classifying them into three additional subcategories:
universal, age-targeted, and selective. In five studies, universal
programs based on immunohistochemistry, either alone or in
combination with the BRAF test, were cost-effective compared with
no screening, while in two studies age-targeted programs with a
cutoff of 70 years were cost-effective when compared with age-
targeted programs with lower age thresholds.
Conclusion: Universal or o70 years–age-targeted CRC-based LS
screening programs are cost-effective and should be implemented
in the “real world.”
Genet Med advance online publication 4 January 2018
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INTRODUCTION
Lynch syndrome (LS) is the most common cause of inherited
colorectal cancer (CRC), accounting for about 3% of newly
diagnosed cases, and results from a mutation in one of the
DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6,
and PMS2). As LS is associated with an increased risk of
colorectal, endometrial, and other cancers, it is important to
identify both the probands and their family members.1
In 2009, the Evaluation of Genomic Applications in Practice
and Prevention Working Group recommended testing for LS
in individuals with newly diagnosed CRC to reduce cancer
morbidity and mortality in relatives.2 The working group
declared that there is a moderate certainty that this would
provide moderate population benefit, but it did not
recommend a specific genetic testing strategy among the
several examined, nor did it deal with implementation issues.2
Thereafter the US Department of Health and Human Services
adopted the following as a Healthy People 2020 develop-
mental objective:3 “Increase the proportion of persons with
newly diagnosed colorectal cancer who receive genetic testing
to identify Lynch syndrome (or familial colorectal cancer
syndromes).”
Although genomic information has the potential to improve
the delivery of patient-centered care through tailored
preventive, diagnostic, and treatment strategies, there is a
considerable gap between discoveries in genomics research
and the translation of these findings into genetic services that
benefit patients.4,5 A previous study highlighted the consider-
able variation in uptake of LS screening among health-care
organizations,6 while other authors have stated that under-
screening for LS should be considered a form of a health
disparity.7 Some possible barriers that might hinder the
successful implementation of LS screening programs are
variations in local expertise, availability of laboratory and
genetic counseling services, limited acceptance of genetic
testing and low compliance with surveillance recommenda-
tions by the patient, psychosocial impact on the patient and
family, and the costs of genetic testing.8,9 Therefore, the
widespread implementation of a successful LS screening
program will require a strongly integrated multidisciplinary
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public health approach,9 including a careful evaluation of the
appropriate use of available economic resources.10 As
evidenced by the results of a systematic review on BRCA
genetic testing programs, economic evaluations may allow
an assessment of genetic screening programs in terms of
both their cost and effectiveness and their readiness for
implementation.11
Two previous systematic reviews12,13 of LS economic
evaluations have argued that universal LS screening is cost-
effective compared with not performing genetic testing (no
screening), but not necessarily compared with selective or
age-targeted testing strategies. Accordingly, there are still
several issues that need to be clarified: the cost-effectiveness of
universal screening relative to age-targeted screening, the
comparative cost-effectiveness of different diagnostic strate-
gies, the implications of the use of preventive strategies for
endometrial and ovarian cancer in females with LS, and the
cost-effectiveness of LS screening programs for other potential
target populations, such as women newly diagnosed with
endometrial cancer or primary care patients.
Therefore, in this systematic review, we have carried out a
comprehensive assessment of LS screening programs whose
cost-effectiveness has been subject to an economic evaluation.
Our aim was to recognize clinically and economically feasible
diagnostic and preventive strategies that may be implemented
in the “real world.”
MATERIALS AND METHODS
This systematic review was performed according to the
guidelines set by the Center for Reviews and Dissemination
and by the Cochrane Collaboration.14,15
Inclusion criteria
We included full economic evaluations of LS screening
programs containing genetic testing strategies aimed at
identifying and managing LS in different target populations.
The included studies were required to have evaluated the costs
and benefits of each strategy provided by the screening
program and to have reported the health outcomes in terms of
either life-years gained (LYG) or quality-adjusted life-years
(QALYs) gained. As in the review by Grosse,13 we excluded
partial cost-effectiveness analyses (CEAs) that reported only
estimates of cost per case detected because they did not
consider the impact of preventive strategies and did not
quantify the willingness-to-pay to achieve an improvement in
health status.
Search strategy
The literature search comprised all studies published in
English from inception to August 2017 and present in the
following databases: MEDLINE, Scopus, Web of Science, the
National Health Service Economic Evaluation Database, the
Database of Abstracts of Reviews of Effects, the Health
Technology Assessment Database, the Economics Literature
Index, and the CEA Registry. The search strings were built up
and adapted for each database using the following search
terms: “hereditary nonpolyposis colorectal cancer OR Lynch
syndrome” AND “screening OR genetic test*” AND “health
technology assessment OR economic evaluation OR cost-
benefit OR cost–utility OR cost-effectiveness.” The search
terms used covered information relating to the clinical
condition, the health technology used, and the study design.
The literature search was carried out by two researchers (M.D.
M., E.D.A.), and it also included the examination of reference
lists of previous systematic reviews of LS economic evalua-
tions to identify further potentially relevant studies.
Selection of studies
Two researchers (M.D.M., E.D.A.) independently screened
the titles and abstracts of the retrieved studies and identified
those eligible for a more comprehensive assessment. The full
text of each eligible article was examined and the article was
included in the review if it passed the inclusion criteria.
Data extraction and quality assessment
The information extracted comprised article data (authors,
country, journal, year of publication), methodological features
of the study (type of economic evaluation, analytical model,
outcome measures, time horizon, study perspective, incre-
mental cost and effectiveness data, discount rates, cost-
effectiveness threshold, type of sensitivity analyses), basic
components of the program (clinical condition, target
population, clinical criteria, age cutoffs, tumor testing, genetic
counseling, gene sequencing, preventive strategy, screening of
relatives), and assumptions relating to key model parameters
and cost data used within the model. Data extraction was
performed by two researchers (M.D.M., N.P.) independently
and was reviewed by a third researcher (E.D.A.).
The methodological quality of the included studies was
assessed using the BMJ checklist16 and the Quality of Health
Economic Studies (QHES) list.17 The BMJ tool allows a
detailed qualitative assessment, whereas the QHES tool
provides an overall score for each study. Quality assessment
of all included studies was performed independently by two
researchers (M.D.M., N.P.). Potential differences in the
assessors’ results were resolved by discussion.
Data synthesis
A classification of the LS screening programs evaluated was
carried out to identify and summarize all those studies in
which the authors judged the programs to be cost-effective.
We did not adjust the costs and discount rates of the included
studies to directly compare the retrieved incremental cost-
effectiveness ratios (ICERs). Because assumptions relating to
key model parameters strongly depend on the intervention
context, a direct comparison of ICERs is likely to be
inappropriate to fully assess the cost-effectiveness of screening
programs.18 The classification process was made in five steps:
(i) the structure of each program was summarized in terms of
target population, diagnostic strategy (age cutoff, clinical
criteria, tumor testing, gene sequencing), cascade testing of
the relatives, and preventive strategy; (ii) the outlined
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programs were listed in a table in chronological order and
were tagged according to the Centers for Disease Control and
Prevention (CDC) classification of genomic applications
(Tier);19,20 (iii) the ICERs extracted from each study were
listed in the table according to the specific comparisons made
between programs and were marked as accepted or not
accepted according to the willingness-to-pay thresholds
specified in their studies; (iv) based on their target population,
programs were assigned to specific screening categories and
were listed in different tables; and (v) programs were ranked
in ascending order of ICER and divided into two sections: one
for those with accepted ICERs, the other for those for which
ICERs were not accepted.
Because of the lack of a universally accepted ICER threshold
and the different health-care resources and preferences
among different countries,21 we counted as cost-effective
programs all those with an ICER under the willingness-to-pay
threshold specified in their studies. When the ICER threshold
was not stated in the study, we adopted a threshold we judged
to be appropriate after considering either the economic
literature or the institutional guidelines of the selected
country.
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Figure 1 Flow diagram for selection of economic evaluations of LS screening programs. (Adapted from PRISMA65.) CEA Registry, Cost-
Effectiveness Analysis Registry; DARE, Database of Abstracts of Reviews of Effects; EconLit, Economics Literature Index; HTA Database, Health Technology
Assessment Database; LYG, life-years gained; NHS EED, National Health Service Economic Evaluation Database; QALY, quality-adjusted life-years.
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RESULTS
The literature search initially identified 405 studies. After title
and abstract screening, 25 full-text articles were assessed for
eligibility. A further five studies were subsequently excluded
for the following reasons: one article referred to the same
results contained in another included study,22 one model did
not evaluate health benefits in terms of LYGs or QALYs,23
one article was written in Danish,24 and two studies were
systematic reviews.12,13 Twenty economic evaluations25–44
were finally included in our systematic review. A flow
diagram of literature search results is shown in Figure 1.
General characteristics of studies
The methodological features of the economic evaluations
included are described in Supplementary Table S1 online.
Ten studies were carried out in the United
States,25–27,30–34,39,40 four in the Netherlands,28,36,41,44 and
one each in Denmark,29 Singapore,35 the United Kingdom,37
Germany,38 Taiwan,42 and Canada.43 Fifteen studies
employed a CEA,25–30,32,33,35,36,38,39,41,42,44 three employed a
cost–utility analysis (CUA),31,34,37 and two employed
both CEA and CUA.40,43 All studies assumed a lifetime
time horizon.25–44 The health-care system perspective was
adopted as the viewpoint of analysis in most
studies.25,27–30,35–37,40,41,43,44 Four studies declared a societal
perspective, but none of these included social costs.26,31,32,39
Most economic models used were based on a decision
analysis,26–40,42,43 while a Markov model was applied in 11
studies.28,29,32–35,38,39,42,43 The most frequently used discount
rate for costs and benefits was 3%.26,27,30–35,38–42,44 The ICER
thresholds stated in the studies were in the range 50,000–
100,000 for US dollar–based economic models27,30–34,39,40,42
and in the range 40,000–80,000 for euro-based economic
models.36,38,41,44 The lowest ICER threshold was 20,000
pounds sterling,37 whereas the highest was 159,000 Singapore
dollars.35
Quality assessment
In general, the quality of the economic evaluations included
was good and all but two studies26–39,41–44 achieved a score
greater than 80 according to the QHES checklist
(Supplementary Table S1). Nevertheless, several models did
not comply with some of the methodological requirements
listed in the BMJ checklist (Supplementary Table S2).
Regarding aspects of study design, the viewpoint of analysis
was clearly stated and justified in 11 of 20 economic
evaluations,27,28,30,33–35,37,38,41–43 but the perspective declared
by the authors was not consistent with the costs included in
the analysis in four studies.26,31,32,39 Although adjusting for
health-related quality of life would generally be recommended
for cost-effectiveness analysis,45 10 economic evaluations
did not explain the lack of outcomes in terms of
QALYs.26–29,32,35,38–40,42 Regarding data collection, almost all
studies stated the effectiveness of the health interventions, but
only one43,46 reported the methods of data synthesis. Only
two of five studies using outcomes measured in QALYs
specified the details of the methods used and the subjects
from whom valuations were obtained.34,37 In general,
costs were properly quantified, but only seven studies
considered adjustments for inflation or currency
conversion.29,35,37,40–42,44 Although to different degrees, most
studies gave details of the modeling and parameters
used.26–28,30–39,42,43 The time horizon of the analysis was not
always clearly defined, although it could be deduced from the
model.29,31,40,41,44 Sensitivity analysis was performed in all
economic evaluations:25–44 six studies used only univariate
analysis,25,28,31,39,41,44 while nine studies performed probabil-
istic sensitivity analysis.26,27,33,34,36,38,40,42,43 Furthermore,
most studies reported the range over which variables
varied.25–30,33–35,37–44 All economic evaluations provided an
incremental analysis.25–44
Influential parameters and basic assumptions
Basic assumptions of key model parameters were extracted to
evaluate their impact on ICER estimates (Supplementary
Table S3). In general, parameters and assumptions included
in the economic models differed according to the features of
the screening programs evaluated. According to the results
reported by the authors, the most influential parameters were
prevalence of LS, uptake of genetic testing, cost of gene
sequencing, number of relatives tested per proband, uptake of
genetic counseling among relatives, uptake of LS surveillance,
the cost of colonoscopy, risk of CRC for mutation carriers,
risk reduction of CRC with LS surveillance, and discount rate
for cost and benefit (Supplementary Table S4). Most studies
assumed a LS prevalence between 2 and 3% in new CRC
patients,26,27,30,33,34,38,39,42,43 whereas Snowsill37 and Leenen41
assumed respectively a LS prevalence of 8.4% and 4.9% for
new CRC patients up to age 50. Uptake of genetic testing
among cancer patients ranged from 60 to 100%;26–28,30,33,34,36–
39,42–44 notably, Dinh31 assumed 100% of genetic testing
uptake in the general population. Excluding the two studies by
Ramsey,26,27 the overall number of relatives tested per
proband ranged from one to eight.30,33,34,36–40,42,43 The most
favorable assumption, by Sie,36 of eight relatives tested per
proband resulted from a 100% uptake of genetic testing
among relatives. Conversely, Severin38 made the most
conservative assumptions of a 29.5% uptake of genetic
testing among relatives and 1.1 relatives tested per proband.
The prevalence of LS among tested relatives varied between 37
and 50%.26,27,30,33,34,36–39,42–44 Conservative assumptions for
this parameter were used by Mvundura30 and Snowsill12,37
since some tested relatives might not be first-degree biological
relatives, while other authors36,43,44 calculated prevalence
estimates less than 50% because they used data from studies
or databases on LS screening that included also second-
or higher-degree relatives in the cascade testing. Most
studies assumed roughly an 80% uptake of LS
surveillance,30,31,33,34,36–39,41–44 but two studies proposed a
100% uptake.32,35 Estimates of the lifetime risk of CRC for
mutation carriers in the absence of prevention strategies
varied widely among the studies. It was higher in the least
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recent analyses (80%)26,27,29 and considerably lower in the
latest studies.30,32–35,37–39,41,43,44 Estimates of reduction in risk
of CRC in mutation carriers adhering to LS surveillance
programs was assumed to be 56–62% in most
studies.26,27,29,30,32–37,39–42,44 Severin adopted the most con-
servative percentage of 52%,38 whereas the Canadian Agency
for Drugs & Technologies in Health model assumed the most
favorable percentage of 68% CRC risk reduction.43 Several
studies reported percentages greater than 99% for both
sensitivity and specificity of MMR genes sequencing 30,38–
40,43,44 (Supplementary Table S5), but a lower sensitivity was
assumed by Ramsey (87%),26,27 Dinh (90%),31 and Snowsill
(90%).37 The sensitivity ranges of microsatellite instability
(MSI) and immunohistochemistry (IHC) tests were
respectively 76–91%26,27,30,33,34,37–39,42 and 77–92%,30–34,37–
40,42,43 whereas specificity ranges were 79–93% for
MSI26–28,30,33,34,37–39,42 tests and 70–91% for IHC
tests.30–34,37–40,42,43 Being context-specific, cost assumptions
(Supplementary Table S6) are not directly comparable;
single-gene sequencing costs ranged from 600 to 1,200 dollars
in American studies,30–34,39,40 whereas, with euro-based
models, it was much more expensive in the German study
(3,836 euros)38 than in Dutch studies (538–814 euros).36,41,44
In general, family mutation testing was far less expensive than
single-gene sequencing.30,31,33,34,36–44 Colonoscopy costs ran-
ged from 500 to 950 dollars in American studies25,30–34,39 and
from 144 to 393 euros in European studies,28,29,36,38,41,44
excepting the model by Snowsill (395 pounds sterling).37
Classification of LS screening programs
We classified the screening programs with reference to the
basic design components for each program (Supplementary
Table S7). All studies included programs that considered
CRC,25–44 while endometrial cancer and ovarian cancer
were addressed respectively in nine31–34,37,39,41,43,44 and in
five studies.33,34,39,41,43 Most studies focused on newly
diagnosed CRC patients,26–28,30,33,34,36–39,41–43 but five
additional different target populations were also
considered.25,29,31,32,35,39,40,44
Regarding the diagnostic strategies covered by the evaluated
programs, 14 studies included clinical criteria;26–29,31–34,37–
39,41,43,44 specifically, the Amsterdam criteria were used in
eight studies,28,29,32–34,37–39 Bethesda guidelines in nine
studies,26,27,33,34,38,39,41,43,44 and computational models in
four studies.31,33,34,39 Seven studies used a specific age cutoff
to select people for inclusion in the screening
program,30,32,36,37,41,43,44 while preliminary tumor testing
was employed in 15 studies.26–28,30,32–34,36–39,41–44 When we
examined diagnostic strategies in more detail, we discovered
that MSI testing was used in 13 studies,26–28,30,33,34,36–39,41,42,44
IHC testing in 12 studies,30,32–34,36–39,41–44 BRAF testing in 8
studies,30,33,34,37–39,42,43 and MLH1 hypermethylation testing
in four studies.36,41,43,44 All studies but one31 included genetic
counseling of individuals involved in the screening. Genetic
testing involving all four MMR genes was performed in 15
studies,30–44 whereas EPCAM sequencing was included in
only three studies.40,41,44 Genetic counseling and cascade
testing of relatives of affected patients were included
respectively in 15 (ref. 26–28,30,33,34,36–44) and 16 (ref.
26–28,30,31,33,34,36–44) economic models.
Regarding preventive strategies, colonoscopy was included
in all studies,25–44 gynecological surveillance and/or prophy-
lactic total abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAHBSO) in eight,31,33,34,37,39,41,43,44 and
aspirin chemoprevention in one study.38 Use of tumor
MMR genes status to support adjuvant chemotherapy choices
was modeled in only one study.43
Taking into account the target populations included in the
programs, we were able to identify six categories of screening
program for LS (Supplementary Table S8): (i) CRC-based,
i.e., screening of newly diagnosed CRC patients;26–28,30,33,34,36–
39,41–43 (ii) endometrial cancer (EC)–based, i.e., screening of
newly diagnosed EC patients;32,44 (iii) general population–
based, i.e., screening of all individuals of a specific age;25,31,39
(iv) LS family registry–based, i.e., screening of individuals
from families referred to a LS registry;29 (v) cascade testing–
based, i.e., screening of first-degree relatives (FDRs) of LS
carriers;35 and (vi) genetics clinic–based, i.e., screening of
patients referred to a genetics clinic for evaluation of
hereditary CRC and polyposis (CRCP) syndromes.40 For the
first category, i.e., CRC-based LS screening programs, three
additional specific approaches or subcategories were identi-
fied: (ia) universal CRC-based, i.e., screening of all newly
diagnosed CRC patients, without performing a preliminary
selection in terms of age or clinical criteria;27,30,33,34,38,39,42,43
(ib) age-targeted CRC-based, i.e., screening of only those
newly diagnosed CRC patients who fall below specific age
cutoffs such as 50, 60, or 70 years;30,36,37,41,43 (ic) selective
CRC-based, i.e., screening of only those newly diagnosed CRC
patients who meet clinical criteria such as the Amsterdam II
criteria or the Revised Bethesda Guidelines (RBG)
criteria.26–28,33,34,38,39,43
Screening programs accepted as cost-effective
LS screening programs were accepted as cost-effective if their
ICERs fell under the willingness-to-pay thresholds reported in
their studies (Supplementary Table S9). For studies without
stated ICER thresholds, we selected the following thresholds
by reviewing the relevant economic literature and institutional
guidelines: US dollars 100,000/QALY or LYG47 for both
Brown’s study25 and Ramsey’s study,26 euros 80,000/QALY or
LYG36,48 for Kievit’s study,28 and Canadian dollars 50,000/
QALY or LYG49 for the Canadian Agency for Drugs &
Technologies in Health study.43 Since there was no defined or
proposed ICER threshold in Denmark,50,51 we accepted all the
cost-effective programs extracted by Olsen’s study29 because
their ICERs were well below the thresholds used in the other
European studies included.36–38,41,44
Depending on their category, cost-effective programs were
listed in different tables and were ranked in ascending order
of ICER. Each specific category table was split into two
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sections, one for programs with accepted ICERs and another
for programs where ICERs were not accepted.
Universal CRC-based LS screening programs accepted as
cost-effective
Most cost-effective programs with an accepted ICER
(Table 1) included, as a preliminary tumor test, either IHC
testing alone or IHC testing in combination with a BRAF
test.30,33,34,39,42 All programs included cascade screening of
relatives.27,30,33,34,39,42,43 Colonoscopy surveillance was the
most widely used preventive strategy.27,30,33,34,39,42,43 Several
programs also included TAHBSO at age 40–45 years or after
completion of childbearing.33,34,39,43 All but one43 of the
diagnostic strategies used were categorized as tier 1.
Universal programs based on IHC plus BRAF testing
achieved accepted ICERs when compared with either no
screening or with age-targeted CRC-based programs using an
age cutoff of 50 years.30,33,34,39,42 Conversely, these programs
did not achieve accepted ICERs when compared with selective
CRC-based screening programs.38,39 Universal programs
based on IHC testing resulted in accepted ICERs when
compared with either no screening or with age-targeted CRC-
based programs using an age cutoff of 50 years,30,42 but did
not result in accepted ICERs when compared with universal
programs based on IHC testing plus BRAF testing.30,42,43 One
universal program based on IHC testing plus MLH1
hypermethylation testing showed an accepted ICER when
compared with an age-targeted CRC-based program using an
age cutoff of 70 years.43 Universal programs based on MSI
testing showed accepted ICERs when compared with no
screening and with age-targeted CRC-based programs using
an age cutoff of 50 years,27,30,42 but conversely did not show
accepted ICERs when compared with universal programs
based on IHC testing.30,42 Universal programs based on up-
front gene sequencing in all CRC patients never resulted in
accepted ICERs.27,30,33,34,38,39,42
Age-targeted CRC-based LS screening programs accepted as
cost-effective
Most cost-effective programs with an accepted ICER
(Table 2) used an age cutoff of 50 years and included
different preliminary tumor tests as part of the diagnostic
strategy.30,37 All programs included cascade screening of
relatives and 2-year colonoscopy surveillance.30,36,37,41,43 Most
diagnostic strategies were categorized as tier 2.30,36,37,41
Programs based on an age cutoff of 50 years and
preliminary tumor testing achieved accepted ICERs when
compared with no screening.30,37 Programs based on an age
cutoff of 70 years and preliminary tumor testing gave
accepted ICERs when compared with age-targeted programs
with lower age thresholds.36,41 Programs based on up-front
gene sequencing in CRC patients o50 years old achieved
accepted ICERs when compared with no screening,30,37 but
conversely did not achieve accepted ICERs when compared
with programs based on an age cutoff of 50 years and
preliminary tumor testing.30,37
Selective CRC-based LS screening programs accepted as cost-
effective
Most selective programs with accepted ICERs used Bethesda
guidelines or the MMRpro computational model to select
CRC patients for genetic screening26,27,33,34,39,43
(Supplementary Table S10). IHC and MSI testing were
most frequently used as preliminary tumor tests.26–28,33,34,39
Some older programs used diagnostic strategies based on
outdated clinical criteria, such as the first edition of the
Bethesda guidelines, and the sequencing of only two MMR
genes.26–28 Most programs included cascade screening of
relatives.26–28,33,34,39,43 Colonoscopy surveillance intervals
included in the preventive strategies ranged from 1 to 3
years. None of the diagnostic strategies used in selective
programs with accepted ICERs belonged to the tier 1
category.26–28,33,34,39,43
Programs that used MMRpro for the clinical criteria and an
IHC test as the preliminary tumor test achieved accepted
ICERs when compared with no screening,33,34,39 while one
program based on RBG and IHC testing provided accepted
ICERs when compared with a program based on MMRpro
and IHC testing.33,34 One program based on RBG and IHC
plus BRAF testing did not give accepted ICERs when
compared with no screening.38
Other LS screening programs accepted as cost-effective
One EC-based program with an age cutoff of 70 years showed
accepted ICERs when compared both with programs with an
age cutoff of 50 years and with programs with an age cutoff of
70 years and RGB as the clinical criteria used.44 One EC-based
program based on clinical criteria and IHC testing achieved an
accepted ICER when compared with a program based on an
age cutoff of 50 years and clinical criteria.32 General
population-based programs, focused on individuals older than
20 years and with a mutation risk greater than 5% according to
the PREMM126 model, gave accepted ICERs when compared
with a selective CRC-based program.31 A LS family registry–
based program showed accepted ICERs in an outdated Danish
study that evaluated the cost-effectiveness of LS surveillance in
at-risk families.29 A cascade testing–based program focused on
FDRs of LS patients dominated an unselective surveillance
program with no genetic testing.35 Genetics clinic–based
programs based on next-generation sequencing (NGS) panels,
including genes associated both with highly penetrant CRCP
syndromes and LS, achieved accepted ICERs when compared
with a CRC-based program.40
DISCUSSION
The increased use of economic evidence would facilitate the
effective translation of research findings into medical
practice.52 As for other genetic testing programs,11 a systematic
review of economic evaluations is the most useful way to
identify all potentially cost-effective LS screening programs and
to assess their suitability in health-care services.53
LS screening programs were divided into six categories
depending on the target population: thus, we identified
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CRC-based, EC-based, general population–based, LS family
registry–based, cascade testing–based, and genetics clinic–
based LS screening programs. For CRC-based LS programs,
three additional subcategories were identified: universal CRC-
based, age-targeted CRC-based, and selective CRC-based LS
screening programs. LS screening programs basically consist
of three subunits: diagnostic strategy, cascade screening, and
preventive strategy. In each screening category, programs
differed from each other according to the components
included in their subunits. In this regard, diagnostic strategies
showed the highest variability, and thus represented the
hallmark of each program. Cascade screening of relatives was
included in almost all programs. Because it allowed
identification and surveillance of additional mutation carriers,
cascade screening was a key component in improving cost-
effectiveness.26–28,30,31,33,34,36–44 All preventive strategies
included colonoscopy surveillance. TAHBSO was included
in several programs, but it did not affect cost-effectiveness
because its adherence estimates were generally
conservative.33,34,39,41,43,44 When included, EC surveillance
resulted in additional costs without any health
benefits,31,33,34,41,44 in accord with the lack of proven benefit
for gynecologic surveillance.54 Aspirin chemoprevention as a
preventive strategy in addition to colonoscopy was modeled
in one study, but it had little influence on the cost-
effectiveness of LS screening.38
CRC-based screening programs were the most investigated
category in the included studies.26–28,30,33,34,36–39,41–43 All
three subcategories covered programs with accepted ICERs,
but only universal programs included diagnostic strategies
that belong to tier 1, namely those that may have a significant
positive impact on public health according to the CDC’s
Office of Public Health Genomics classification of genomic
applications.19,20 An additional concern is that the clinical
criteria included in selective programs might be insufficiently
sensitive or specific to identify patients who need further
investigation and might also be difficult and costly to
introduce into routine practice.39,55,56 Furthermore, it is likely
to be challenging to identify the most cost-effective tumor
testing approach for the selection of CRC patients for gene
sequencing. Therefore, the choice between IHC and MSI
testing as initial screen and the choice between BRAF and
MLH1 hypermethylation testing as additional tumor testing
for each screening program should depend on context-specific
factors such as the available technologies, the staffing
expertise, the physician preferences, the availability of specific
screening protocols for colon cancer patients, and billing and
reimbursement constraints. However, the continuing decrease
in the cost of genetic testing will lead to a streamlining of the
diagnostic strategies and an improvement of cost-effectiveness
for the CRC-based screening.
The cost-effectiveness of EC-based screening was assessed
in only two of the included studies.32,44 Although both
economic evaluations identified programs with accepted
ICERs, it was problematic to directly compare and sum up
the results because of the heterogeneity of their components.
We found that an age cutoff of 70 years is probably better
than a lower age cutoff in terms of cost-effectiveness.
However, as current guidelines do not recommend a single
age cutoff for EC-based LS screening,1,54,57,58 further inves-
tigation would be needed to shed light on this.
The cost-effectiveness of general population–based screening
using criteria determined by the PREMM126 model to select
people for referral for gene sequencing should be interpreted
with care.31 Because PREMM126 was not validated in the general
population,59 its use in this context may not be appropriate.60
The cost-effectiveness of LS screening where NGS panels
were used to test patients referred to cancer genetics clinics
has both positive and negative aspects.40 Thus, on the plus
side, although we recognize that NGS panels provide a more
comprehensive evaluation of the genetics of hereditary
colorectal cancers, the lack of information on the criteria by
which patients were referred to genetics clinics made it
impossible for us to perform a full assessment of the program.
Therefore, additional studies are required to determine
whether these technologies can be successfully employed
within LS screening programs.
As cascade screening of relatives was included in almost all
programs with accepted ICERs, the number of relatives tested
per proband was generally a key factor for cost-effectiveness.
Several authors have recognized that LS screening programs
are progressively more cost-effective as more relatives are
tested.30,33,38,39,43 However, the number of relatives tested per
proband varied widely across the studies, ranging from one to
eight.30,33,34,36–40,42,43 In some models, the number of relatives
tested was also influenced by other parameters, such as the
uptake of genetic counseling (ranging from 45 to 52%)
30,37,40,42 and the uptake of genetic testing (ranging from 29 to
100%)30,33,34,36–40,42,43 among relatives. The broad variability
of these parameters results from a lack of data on the
implementation of each activity in specific clinical
contexts.10,61 Indeed, several factors, such as the specific
features of the health-care system, differences in the genetic
testing delivery model and the approaches used to contact and
test relatives at risk of LS, cost limitations, and ethical
considerations, may impact screening rates.62 Furthermore,
several patient-related aspects could also affect the uptake of
genetic testing: for example, socioeconomic status, family
communication barri`ers and psychosocial inhibitions
involved in informing relatives, and the family history of
cancer.62 Sharing genetic test results with family members and
caregivers can be of paramount importance in increasing
screening rates of relatives and in improving the effectiveness
and cost-effectiveness of LS screening.62,63
Our systematic review can help inform health decision
makers of the opportunities and challenges involved in
integrating LS screening in public health policies.10,64 Com-
pared with previous reviews,12,13 ours is a more comprehensive
classification of all cost-effective LS screening programs and we
assessed their feasibility within the related health-care contexts.
We considered all target populations examined in the
economic studies to provide a broad overview of the various
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available LS screening programs. We analyzed full-service
programs so that we could take into account both the health
benefits and the costs of the cascade effect generated by genetic
screening. On the other hand, we did not provide a definite
evaluation of cost-effectiveness of different tumor testing
approaches because we consider this an extremely context-
sensitive issue. Another limitation of our study is that we did
not assess other factors that could have an impact on the final
implementation of the programs, other than cost-effectiveness,
such as patient needs and resources, external policy and
incentives, or structural characteristics of genetic services. An
analysis of these factors should be performed and adjusted
according to the specific contexts and settings where the
program is going to be adopted. We did not assess the cost-
effectiveness of integrating innovative testing technologies, such
as the NGS panels or the tumor testing for somatic mutations,
in CRC-based screening programs because no relevant
economic evaluations have been identified.
In conclusion, from a health-care perspective, the cost-
effectiveness of both universal and age-targeted CRC-based LS
screening is acceptable in terms of willingness-to-pay for
health gains. Therefore, as recommended by most US and
European guidelines,1,54,57,58 universal or o70 years age-
targeted CRC-based LS screening programs should be
implemented in health practice. However, both the design
of the screening program and the implementation process will
need to be tailored to the characteristics of target populations
and health-care systems to ensure the translation of cost-
effectiveness evidence into the “real-world.”
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the version of the paper at
http://www.nature.com/gim
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